Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome | Clinical Trial - Marfan Sartan
Description:
The goal of this trial was to evaluate treatment with losartan compared with placebo among patients with Marfan syndrome.
Contribution to the Literature: The Marfan Sartan trial failed to show that losartan prevented aortic root dilatation.
Study Design
- Randomized
- Parallel
- Blinded
Marfan patients were randomized to losartan (n = 153) versus placebo (n = 150). The dose of losartan was 50 mg for those <50 kg and 100 mg for those ≥50 kg.
Inclusion criteria:
- Patients at least 10 years of age with Marfan syndrome
Exclusion criteria:
- Planned or prior aortic root surgery
- Total number of enrollees: 303
- Duration of follow-up: Median 3.5 years
- Mean patient age: 30 years
- Percentage female: 56%
Principal Findings:
The aortic root diameter increased 0.44 mm/year in the losartan group versus 0.51 mm/year in the placebo group (p = 0.36).
Secondary outcomes:
- Mean systolic blood pressure was 5 mm Hg lower in the losartan group vs. the placebo group
- Aortic surgery: 9.9% vs. 8.8%, respectively, for losartan vs. placebo
- Deaths: 0 vs. 2%, respectively, for losartan vs. placebo
Interpretation:
Among patients with Marfan syndrome, losartan was unable to prevent aortic root dilatation, deaths, or aortic surgery despite a reduction in blood pressure. Beta-blocker therapy remains the standard therapy for Marfan patients.
References:
Milleron O, Arnoult F, Ropers J, et al. Marfan Sartan: a Randomized, Double-Blind, Placebo-Controlled Trial. Eur Heart J 2015;May 2:[Epub ahead of print].
Keywords: Adrenergic beta-Antagonists, Angiotensin II Type 1 Receptor Blockers, Aorta, Blood Pressure, Cardiac Surgical Procedures, Dilatation, Double-Blind Method, Follow-Up Studies, Heart Defects, Congenital, Losartan, Marfan Syndrome, Primary Prevention, Systole
< Back to Listings